Abstract:

LIDO is a multi-site observational study of unrecognized depression and its quality of life and economic correlates. The LIDO study is currently underway in 6 countries: Australia, Brazil, Israel, Russian Federation, Spain and the US. Participating primary care sites are in process of recruiting 150 depressed patients who have not received treatment for depression in the past 3 months. In all, approximately 900 patients are being followed over the course of one year to determine their concurrent medical conditions, quality of life, health care utilization, change in depression status and course of treatment. Strict adherence to study protocol across these six international sites promises to yield high quality data and important information regarding the cross-cultural course of depression in primary care, as well as to characterize the change in functioning, quality of life and health care utilization among depressed patients over time.

Background and Rationale

Depression is a serious health problem that often goes undiagnosed and untreated by primary care physicians. Little is known cross-culturally about the burden of depression, in terms of economic costs and quality of life. In US studies, depressed patients are high consumers of general medical resources in addition to their use of mental health services, but it is not well understood if this trend is seen cross-culturally, or when taking into account co-morbid conditions and functional limitations.

The primary objective of the LIDO study is to assess the quality of life and economic correlates of recognized clinical depression in primary care settings. This will be done in a multi-center, cross-cultural observational study design with repeated measures.

Secondary objectives of the LIDO study are:

1) To determine change in the functioning, quality of life (QoL), and medical care utilization of people with major depression.
2) To describe potential predictors of change for the outcomes listed above, including severity of depression, comorbid physical conditions, treatment status and demographic characteristics.
3) To describe differences in QoL and resource utilization between treated and non-treated patients with major depression.
4) To further refine several research tools related to QoL.
5) To assess the burden of depression on a primary care patient population.

Patients using primary care facilities are screened for depressive symptoms using the Center for Epidemiological Studies Depression (CES-D) Scale with a cutoff point of 16. Those meeting inclusion criteria are given the Composite International Diagnostic Interview (CIDI), which has been modified for recency of symptoms, to confirm the diagnosis of current depression. If other study criteria are satisfied, those scoring positive on the CIDI (using DSM IV Criteria) are enrolled in the study for one year of followup in which depression status, health care utilization, functional status and quality of life are monitored. Site-specific estimates of cost of care are gathered in each country and are standardized to allow for cross-cultural comparisons. The attending primary care physician is made aware of the depression diagnosis of each patient at the beginning of the one-year follow up.

Activities

a) Study Design

The study is organized in 4 phases (Figure 1). The Planning Phase began with international meetings held in Leipzig and Seattle (1997) during which the study design and collaborative relationships were determined.

During the Recruitment Phase, international sites were enrolled on a staggered entry pattern starting with a 3-day orientation, which involved standardized training in LIDO protocol and CIDI administration. Recruitment and patient enrollment activities were begun and monitoring was done at mid and endpoints of recruitment in accordance with uniform established study criteria. The Follow-up Phase involves repeated measures, data management, and continued site monitoring. To date, four sites have completed recruitment with the remaining sites ending this summer. Plans are well underway for the Analytic Phase, which begins summer 1999 after all sites complete recruitment.

b) Site Monitoring

Four separate monitoring visits per site are conducted by the Coordinating Center to ensure that all aspects of data collection, study management and interview procedures are performed in compliance with established study design and protocols. These visits also serve to insure open lines of communication and the opportunity to solve the unique problems arising at each site.

(continued on p 49)
Because validity of the diagnosis of depression is critical to the LIDO study, a site-specific CIDI Monitoring System was established at each site to ensure the quality, consistency, and uniformity in the CIDI interview data.

3. Study Organization

Health Research Associates (Seattle, WA, USA) serves as the international Coordinating Center for the LIDO study. The Research Team (consisting of representatives from five international groups) provides scientific oversight for the study, and a number of Study Advisors bring areas of expertise to the effort. These groups, along with the six site investigators, comprise an overall Steering Committee for the study.

Future Directions

Analytic plans specific to depression, economic and quality of life outcomes have been developed and will guide the entire publication process. Data collection is expected to be completed by the end of summer, 2000. The first abstracts for presentation at scientific meetings are underway and manuscripts are being developed at those sites which are further into follow-up. The end of recruitment will start the first round of Phase 1 manuscripts in January 2000.

Requests for information regarding the LIDO Study should be directed to: Mona Martin, Lido Coordinating Center, Health Research Associates Inc, 4900-9th Avenue NW, Suite 201, Seattle, Washington 98107, USA. E-mail: hraineau@accessone.com or Dr. Diane Jones-Palm, Lido Project Coordinator. Email: dianej@act.com.

Figure 2: Overall Study Organization

LIDO GROUP
LIDO Site Principal Investigators:
Dr. Marianne Amir, Ben-Gurion University of the Negev, Beer Sheva, Israel
Dr. Ramona Lucas, Barcelona, Spain
Dr. Marcelo Fleck, University of the State of Rio Grande do Sul, Porto Alegre, Brazil
Dr. Aleksandr Lomachenkov, V.M. Bekhterev Psychoneurological Research Institute, St. Petersburg, Russian Federation
Dr. Helen Hermann, St. Vincent's Mental Health Service, Melbourne Australia
Dr. Donald Patrick, University of Washington, Seattle, Washington, USA

LIDO Research Team:
Dr. Don Buesching, Dr. Mike Treglia, Eli Lilly and Company (Sponsor), Indianapolis, IN, USA
Ms. Mona Martin, Dr. Diane Jones-Palm, Dr. Don Bushnell, Health Research Associates, Inc (Coordinating Center), Seattle, Washington, USA
Dr. Rex Billington, WHO Mental Health Division, Geneva, Switzerland
Dr. Stephen McKenna, Galen Research, Manchester, UK
Dr. Donald Patrick, Principal Consultant to Study, University of Washington, Seattle, Washington, USA

LIDO Study Advisors:
Prof. Per Bech, MD, Psychiatric Research Unit, Frederiksborg General Hospital, Denmark
Mr. Daniel Chisholm, Centre for the Economics of Mental Health, London, UK
Dr. Paula Diehr, Department of Biostatistics, University of Washington, Seattle, Washington, USA
Prof. Martin Knapp, PhD, Centre for the Economics of Mental Health, London, UK
Dr. Donald Patrick, University of Washington, Seattle, Washington, USA
Dr. Greg Simon, Center for Health Studies, Seattle, Washington, USA
Dr. Mario ter Smitten, WHO-CIDI Training and Reference Centre, University of Amsterdam, The Netherlands
Prof. Willem (Wim) van den Brink, MD PhD, Haarlem, The Netherlands